

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ART UNIT:

EXAMINER: Gerstl

1614

1

Application of

: Kevin Cusack et al.

Serial No.

: 09/777,554

Filed

: February 6, 2001

Entitled

: BENZOTHIAZOLE DERIVATIVES

Attorney Docket No. BBC-077/A

Asst. Commissioner for Patents Washington, D.C. 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

1/11/03

Date of Signature and of Mail Deposit

By:

TRANSMITTAL LETTER

Sir/Madam:

Transmitted herewith are: [X] Reply Under 37 C.F.R. §1.111; and [X] An Acknowledgement Postcard; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

- [X] A fee for additional claims is not required.
- [] A fee for additional claims is required. The additional fee has been calculated as shown below:

| TOTAL FEES DUE | | | | | = |
|--|---------------------|------------------------|---------------------|--------|----------|
| FIRST INTRODUCTION OF MULT. DEPENDENT CLAIM +\$280 | | | | | = 0.00 |
| INDEPENDENT | | | 0 | × \$84 | = 0.00 |
| TOTAL CLAIMS | | | 0 | ×\$18 | = 0.00 |
| | AFTER AMENDMENT | PREVIOUSLY PAID FOR | CLAIMS | IGATE. | TEES DOS |
| | CLAIMS REMAINING | HIGHEST NUMBER | NUMBER OF EXCESS | RATE | FEES DUE |

Application No.: 09/777.554 Attorney Docket No.: BBC-077/A

PAYMENT OF ADDITIONAL FEES

[X] The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16 or 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No. 010025**. A duplicate copy of this transmittal letter is transmitted herewith.

PETITION FOR EXTENSION OF TIME

| Į J | Extension is requested under 37 CFR 1.136(a), and the following extension fee is applicable for the |
|-----|--|
| | paper(s) filed herewith: [] \$110.00 for response within first month pursuant to 37 CFR 1.17(a)(1); |
| | [] \$400.00 for response within second month pursuant to 37 CFR 1.17(a)(2); |
| | [] \$920.00 for response within third month pursuant to 37 CFR 1.17(a)(3); |
| | [] \$1,440.00 for response within fourth month pursuant to 37 CFR 1.17(a)(4). |
| | [] \$1,960.00 for response within fifth month pursuant to 37 CFR 1.17(a)(5). |
| | |

[X] The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to **Deposit Account No.** 010025. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Gayle B. O'Brien Agent for Applicants Registration No. 48,812 Abbott Bioresearch Center, Inc. 100 Research Drive

Garle O'Brien

Worcester, MA 01605-4314 Telephone: (508) 688-8053 Telefax: (508) 688-8110



PATENT Attorney Docket No. BBC-077A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Cusack et al :

APPLICATION NO.:

09/777,554

FILED:

February 6, 2001

FOR:

Benzothiazole Derivatives:

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

EXAMINER: Gerstl, Robert

ART UNIT: 1626



REPLY UNDER 37 C.F.R. §1.111

This is in reply to the Office Action mailed October 17, 2002, the period for response thereto having been set to expire on January 17, 2003.

Please amend the above-identified application as follows: